Project Grant R21DA066888
Award Date 8/15/26
Completion Date 7/31/28
Dollars Obligated $506K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richland, WA 99354, USA
Similar Awards
- The National Institute of General Medical Sciences awarded Battelle Memorial Institute's Pacific Northwest National Laboratory $492,167 on August 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a high-throughput multiomic platform for simultaneous single-cell profiling of proteins, transcripts, and metabolites. The platform integrates novel chemistry, advanced mass spectrometry, and automated nanodroplet processing to analyze thousands of individual...
- The Defense Threat Reduction Agency awarded Battelle Memorial Institute $999,996 on February 9, 2026, under the Scientific Research - Combating Weapons of Mass Destruction program (CFDA 12.351) to develop a polymeric/protein nanoparticles (PNP) platform for delivering episomal DNA constructs with tetracycline-inducible promoters to neuronal tissues. The recipient will synthesize neuron-targeted PNPs guided by a proprietary artificial intelligence/machine learning model that optimizes particle...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded Nanos, Inc. $613,456 on September 11, 2025, under the Biomedical Research and Research Training program (CFDA 93.859) to develop and test a topical nitrite ointment that reverses nitroglycerin tolerance. Nanos, Inc. will formulate a water-in-oil ointment for topical nitrite application designed to enable slow uptake into circulation and prolong...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded $323,090 to Tektonyx Bio, Inc. on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859, Assistance Listing R43GM165195). Tektonyx Bio is developing a semi-synthetic organism platform for the production of next-generation protein therapeutics. The organism harbors two synthetic nucleotides that form an unnatural base...
- The National Institute of Allergy and Infectious Diseases awarded Oregon Health & Science University $731,581 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanobody-based diagnostics for tuberculosis. The project addresses the clinical challenge of TB diagnosis in resource-limited settings. Current point-of-care tests lack sufficient sensitivity, and laboratory-based diagnostics require complex infrastructure unavailable in...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Virginia Polytechnic Institute & State University $733,233 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel nitroxoline analogs for oral treatment of drug-resistant Neisseria gonorrhoeae and Chlamydia. The project addresses the dual public health challenge posed by these sexually transmitted infections....
- The National Institute of Allergy and Infectious Diseases awarded $185,644 to the University of California, Berkeley on August 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a high-throughput pipeline for discovering novel antimicrobial compounds produced by actinomycetes with activity against Mycobacterium tuberculosis. The research pipeline uses 3D-printed assay plates to grow rare actinomycetes in interaction pairs, a condition that triggers...
- The National Institute of Allergy and Infectious Diseases awarded the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center division, $422,125 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize hit compounds for targeted protein degradation in Mycobacterium tuberculosis. The research spans two specific aims. The first aims to identify compound classes that directly bind the ClpC1...
- The National Institute of Allergy and Infectious Diseases awarded Trudeau Institute Inc. $332,414 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the mechanism of action of tuberculocidal compound TI-507 and validate NAD kinase (PPNK) as a novel therapeutic target in Mycobacterium tuberculosis. TI-507, initially identified as a human sphingosine kinase inhibitor, demonstrates activity against MTB with an IC50 of 22 mM, kills persister...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded $855,000 to UT-Battelle LLC (Oak Ridge National Laboratory) on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to develop structurally expanded bifunctional chelators for targeted radiopharmaceuticals in cancer diagnosis and treatment. The award funds research to redesign chelating frameworks that bind radiometal cations and attach targeting vectors to cancer...